Revisiting VISTA: Nonperfusion and Aflibercept

Charles Wykoff, MD, PhD

Show Description +

Charles Wykoff, MD, PhD, reviews an analysis of data from the VISTA trial to find out more about the relationship between aflibercept (Eylea, Regeneron) and retinal nonperfusion in diabetic patients.

Posted: 8/13/2017

Up Next

Name: Revisiting VISTA: Nonperfusion and Aflibercept
Uploaded: 2017-08-13T15:18:00+00:00
Description: Charles Wykoff, MD, PhD, reviews an analysis of data from the VISTA trial to find out more about the relationship between aflibercept (Eylea, Regeneron) and retinal nonperfusion in diabetic patients.

Açai-based Surgical Dye

Mauricio Maia, MD, PhD

DEL MAR: Phase 2, Stage 2

David S. Boyer, MD

Mapping Perfusion Density

Richard B. Rosen, MD, DSc(Hon)

Advances in Endoillumination

David Chow, MD

Preoperative Anti-VEGF Therapy During Vitrectomy

Manish Nagpal, MD, FRCS

Digitally Assisted Vitreoretinal Surgery

Marco Mura, MD

Novel Technique for Steroid Injection

Michael Singer, MD

Treatments for VMT

Nathan C. Steinle, MD

Remaining Cost Effective with 'Slurry' Kenalog

Susan M. Malinowski, MD

Novel Technique for Visual Recovery Testing

John B. Miller, MD

Real-World Outcomes of Anti-VEGF Therapy in DME

Thomas A. Ciulla, MD, MBA

Intraoperative OCT in Subretinal Therapeutic Delivery

Lejla Vajzovic, MD

Cytogenetics in Uveal Melanoma

Carol Shields, MD

Back to All Videos

Revisiting VISTA: Nonperfusion and Aflibercept

Charles Wykoff, MD, PhD

Charles Wykoff, MD, PhD, reviews an analysis of data from the VISTA trial to find out more about the relationship between aflibercept (Eylea, Regeneron) and retinal nonperfusion in diabetic patients.

Posted: 8/13/2017

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Revisiting VISTA: Nonperfusion and Aflibercept

Up Next

Revisiting VISTA: Nonperfusion and Aflibercept

More From ASRS: 2017 Coverage